146 related articles for article (PubMed ID: 7924634)
1. Loss of variability in Graves' disease: stimulatory TSH-receptor antibodies bind to the TSH-receptor in a continued, non-pulsatile and non-chaotic fashion.
Schuppert F; Diegelmann B; Geest T; Wagner TO; von zur Mühlen A
Chronobiologia; 1994; 21(1-2):21-32. PubMed ID: 7924634
[TBL] [Abstract][Full Text] [Related]
2. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
3. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
[TBL] [Abstract][Full Text] [Related]
4. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
5. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
6. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
7. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
8. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
Morgenthaler NG; Ho SC; Minich WB
J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
[TBL] [Abstract][Full Text] [Related]
9. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.
Vos XG; Smit N; Endert E; Tijssen JG; Wiersinga WM
Clin Endocrinol (Oxf); 2008 Aug; 69(2):311-7. PubMed ID: 18208575
[TBL] [Abstract][Full Text] [Related]
10. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
[TBL] [Abstract][Full Text] [Related]
11. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
Ochi Y; Kajita Y; Hamazu M; Nagata A
Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the ratio of T3 release stimulating antibodies to TSH-binding inhibiting antibodies during the course of Graves' disease.
Hoermann R; Saller B; Mann K
Horm Metab Res; 1990 Mar; 22(3):183-7. PubMed ID: 1971613
[TBL] [Abstract][Full Text] [Related]
13. [Clinical implications of a new TSH receptor antibody assay (DYNOtest TRAKhuman) in autoimmune thyroid diseases].
Meller J; Schreivogel I; Bergmann A; Morgenthaler N; Hüfner M; Becker W
Nuklearmedizin; 2000; 39(1):14-8. PubMed ID: 10726252
[TBL] [Abstract][Full Text] [Related]
14. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter.
Wallaschofski H; Orda C; Georgi P; Miehle K; Paschke R
Horm Metab Res; 2001 Aug; 33(8):504-7. PubMed ID: 11544566
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study.
Diana T; Brown RS; Bossowski A; Segni M; Niedziela M; König J; Bossowska A; Ziora K; Hale A; Smith J; Pitz S; Kanitz M; Kahaly GJ
J Clin Endocrinol Metab; 2014 May; 99(5):1648-55. PubMed ID: 24517152
[TBL] [Abstract][Full Text] [Related]
16. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
Kung AW; Lau KS; Kohn LD
J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
[TBL] [Abstract][Full Text] [Related]
17. [Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease].
Zöphel K; Wunderlich G; Koch R; Franke WG
Nuklearmedizin; 2000; 39(4):113-20. PubMed ID: 10919162
[TBL] [Abstract][Full Text] [Related]
18. [Spontaneous hypothyroidism in 4 patients with Graves-Basedow disease].
González-González A; Recio Cordova JM; Aznar Ondoño I; Del Monte Jarabo Bueno M
Endocrinol Nutr; 2009 May; 56(5):273-6. PubMed ID: 19627750
[TBL] [Abstract][Full Text] [Related]
19. Production of bioactive rabbit antibodies against the mutated receptor peptide TSH-R-HIS17 and detection of hypertriiodothyroninemia in the rabbit.
Hirooka Y; Mitsuma T; Nogimori T; Ishizuki Y; Sakai J; Naruse M; Fukayama M
Biochem Mol Biol Int; 1993 Mar; 29(3):493-7. PubMed ID: 8097936
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY
Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
